Thursday, July 26, 2007

Celgene 2nd-qtr earnings jump on cancer drug sales

(Reuters) - Excluding one-time items, the company earned 26 cents a
share. On that basis, analysts on average expected 23 cents a
share, according to Reuters Estimates.




Revenue rose 76.4 percent to $348 million.



Read more at Reuters.com Market News

No comments: